Emergency Hemostatic Agent - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511242136

Publication Date:

November 28, 2024

Pages:

137

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Emergency Hemostatic Agent was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Emergency Hemostatic Agent, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Emergency Hemostatic Agent by region & country, by Type, and by Application.
The Emergency Hemostatic Agent market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Emergency Hemostatic Agent.
麻豆原创 Segmentation
By Company
Ethicon
Pfizer
Baxter International
C. R. Bard
The Medicines Company
Anika Therapeutics
Advanced Medical Solutions
Integra LifeSciences
B Braun Melsungen
Gelita Medical
Equimedical
Vascular Solutions
Marine Polymer Technologies
Z-Medica
CryoLife
BioCer Entwicklungs
Biom鈥橴p SAS
Segment by Type:
Gelation Sponge
Oxidized Regenerated Cellulose Based Hemostats
Others
Segment by Application
Hospitals
Surgical Centers
Clnics
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Emergency Hemostatic Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Emergency Hemostatic Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Emergency Hemostatic Agent in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Emergency Hemostatic Agent Product Introduction
1.2 Global Emergency Hemostatic Agent 麻豆原创 Size Forecast
1.2.1 Global Emergency Hemostatic Agent Sales Value (2019-2030)
1.2.2 Global Emergency Hemostatic Agent Sales Volume (2019-2030)
1.2.3 Global Emergency Hemostatic Agent Sales Price (2019-2030)
1.3 Emergency Hemostatic Agent 麻豆原创 Trends & Drivers
1.3.1 Emergency Hemostatic Agent Industry Trends
1.3.2 Emergency Hemostatic Agent 麻豆原创 Drivers & Opportunity
1.3.3 Emergency Hemostatic Agent 麻豆原创 Challenges
1.3.4 Emergency Hemostatic Agent 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Emergency Hemostatic Agent Players Revenue Ranking (2023)
2.2 Global Emergency Hemostatic Agent Revenue by Company (2019-2024)
2.3 Global Emergency Hemostatic Agent Players Sales Volume Ranking (2023)
2.4 Global Emergency Hemostatic Agent Sales Volume by Company Players (2019-2024)
2.5 Global Emergency Hemostatic Agent Average Price by Company (2019-2024)
2.6 Key Manufacturers Emergency Hemostatic Agent Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Emergency Hemostatic Agent Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Emergency Hemostatic Agent
2.9 Emergency Hemostatic Agent 麻豆原创 Competitive Analysis
2.9.1 Emergency Hemostatic Agent 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Emergency Hemostatic Agent Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Emergency Hemostatic Agent as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Gelation Sponge
3.1.2 Oxidized Regenerated Cellulose Based Hemostats
3.1.3 Others
3.2 Global Emergency Hemostatic Agent Sales Value by Type
3.2.1 Global Emergency Hemostatic Agent Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Emergency Hemostatic Agent Sales Value, by Type (2019-2030)
3.2.3 Global Emergency Hemostatic Agent Sales Value, by Type (%) (2019-2030)
3.3 Global Emergency Hemostatic Agent Sales Volume by Type
3.3.1 Global Emergency Hemostatic Agent Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Emergency Hemostatic Agent Sales Volume, by Type (2019-2030)
3.3.3 Global Emergency Hemostatic Agent Sales Volume, by Type (%) (2019-2030)
3.4 Global Emergency Hemostatic Agent Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Surgical Centers
4.1.3 Clnics
4.1.4 Others
4.2 Global Emergency Hemostatic Agent Sales Value by Application
4.2.1 Global Emergency Hemostatic Agent Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Emergency Hemostatic Agent Sales Value, by Application (2019-2030)
4.2.3 Global Emergency Hemostatic Agent Sales Value, by Application (%) (2019-2030)
4.3 Global Emergency Hemostatic Agent Sales Volume by Application
4.3.1 Global Emergency Hemostatic Agent Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Emergency Hemostatic Agent Sales Volume, by Application (2019-2030)
4.3.3 Global Emergency Hemostatic Agent Sales Volume, by Application (%) (2019-2030)
4.4 Global Emergency Hemostatic Agent Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Emergency Hemostatic Agent Sales Value by Region
5.1.1 Global Emergency Hemostatic Agent Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Emergency Hemostatic Agent Sales Value by Region (2019-2024)
5.1.3 Global Emergency Hemostatic Agent Sales Value by Region (2025-2030)
5.1.4 Global Emergency Hemostatic Agent Sales Value by Region (%), (2019-2030)
5.2 Global Emergency Hemostatic Agent Sales Volume by Region
5.2.1 Global Emergency Hemostatic Agent Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Emergency Hemostatic Agent Sales Volume by Region (2019-2024)
5.2.3 Global Emergency Hemostatic Agent Sales Volume by Region (2025-2030)
5.2.4 Global Emergency Hemostatic Agent Sales Volume by Region (%), (2019-2030)
5.3 Global Emergency Hemostatic Agent Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Emergency Hemostatic Agent Sales Value, 2019-2030
5.4.2 North America Emergency Hemostatic Agent Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Emergency Hemostatic Agent Sales Value, 2019-2030
5.5.2 Europe Emergency Hemostatic Agent Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Emergency Hemostatic Agent Sales Value, 2019-2030
5.6.2 Asia Pacific Emergency Hemostatic Agent Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Emergency Hemostatic Agent Sales Value, 2019-2030
5.7.2 South America Emergency Hemostatic Agent Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Emergency Hemostatic Agent Sales Value, 2019-2030
5.8.2 Middle East & Africa Emergency Hemostatic Agent Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Emergency Hemostatic Agent Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Emergency Hemostatic Agent Sales Value
6.2.1 Key Countries/Regions Emergency Hemostatic Agent Sales Value, 2019-2030
6.2.2 Key Countries/Regions Emergency Hemostatic Agent Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Emergency Hemostatic Agent Sales Value, 2019-2030
6.3.2 United States Emergency Hemostatic Agent Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Emergency Hemostatic Agent Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Emergency Hemostatic Agent Sales Value, 2019-2030
6.4.2 Europe Emergency Hemostatic Agent Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Emergency Hemostatic Agent Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Emergency Hemostatic Agent Sales Value, 2019-2030
6.5.2 China Emergency Hemostatic Agent Sales Value by Type (%), 2023 VS 2030
6.5.3 China Emergency Hemostatic Agent Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Emergency Hemostatic Agent Sales Value, 2019-2030
6.6.2 Japan Emergency Hemostatic Agent Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Emergency Hemostatic Agent Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Emergency Hemostatic Agent Sales Value, 2019-2030
6.7.2 South Korea Emergency Hemostatic Agent Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Emergency Hemostatic Agent Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Emergency Hemostatic Agent Sales Value, 2019-2030
6.8.2 Southeast Asia Emergency Hemostatic Agent Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Emergency Hemostatic Agent Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Emergency Hemostatic Agent Sales Value, 2019-2030
6.9.2 India Emergency Hemostatic Agent Sales Value by Type (%), 2023 VS 2030
6.9.3 India Emergency Hemostatic Agent Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Ethicon
7.1.1 Ethicon Company Information
7.1.2 Ethicon Introduction and Business Overview
7.1.3 Ethicon Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Ethicon Emergency Hemostatic Agent Product Offerings
7.1.5 Ethicon Recent Development
7.2 Pfizer
7.2.1 Pfizer Company Information
7.2.2 Pfizer Introduction and Business Overview
7.2.3 Pfizer Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Pfizer Emergency Hemostatic Agent Product Offerings
7.2.5 Pfizer Recent Development
7.3 Baxter International
7.3.1 Baxter International Company Information
7.3.2 Baxter International Introduction and Business Overview
7.3.3 Baxter International Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Baxter International Emergency Hemostatic Agent Product Offerings
7.3.5 Baxter International Recent Development
7.4 C. R. Bard
7.4.1 C. R. Bard Company Information
7.4.2 C. R. Bard Introduction and Business Overview
7.4.3 C. R. Bard Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2019-2024)
7.4.4 C. R. Bard Emergency Hemostatic Agent Product Offerings
7.4.5 C. R. Bard Recent Development
7.5 The Medicines Company
7.5.1 The Medicines Company Company Information
7.5.2 The Medicines Company Introduction and Business Overview
7.5.3 The Medicines Company Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2019-2024)
7.5.4 The Medicines Company Emergency Hemostatic Agent Product Offerings
7.5.5 The Medicines Company Recent Development
7.6 Anika Therapeutics
7.6.1 Anika Therapeutics Company Information
7.6.2 Anika Therapeutics Introduction and Business Overview
7.6.3 Anika Therapeutics Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Anika Therapeutics Emergency Hemostatic Agent Product Offerings
7.6.5 Anika Therapeutics Recent Development
7.7 Advanced Medical Solutions
7.7.1 Advanced Medical Solutions Company Information
7.7.2 Advanced Medical Solutions Introduction and Business Overview
7.7.3 Advanced Medical Solutions Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Advanced Medical Solutions Emergency Hemostatic Agent Product Offerings
7.7.5 Advanced Medical Solutions Recent Development
7.8 Integra LifeSciences
7.8.1 Integra LifeSciences Company Information
7.8.2 Integra LifeSciences Introduction and Business Overview
7.8.3 Integra LifeSciences Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Integra LifeSciences Emergency Hemostatic Agent Product Offerings
7.8.5 Integra LifeSciences Recent Development
7.9 B Braun Melsungen
7.9.1 B Braun Melsungen Company Information
7.9.2 B Braun Melsungen Introduction and Business Overview
7.9.3 B Braun Melsungen Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2019-2024)
7.9.4 B Braun Melsungen Emergency Hemostatic Agent Product Offerings
7.9.5 B Braun Melsungen Recent Development
7.10 Gelita Medical
7.10.1 Gelita Medical Company Information
7.10.2 Gelita Medical Introduction and Business Overview
7.10.3 Gelita Medical Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Gelita Medical Emergency Hemostatic Agent Product Offerings
7.10.5 Gelita Medical Recent Development
7.11 Equimedical
7.11.1 Equimedical Company Information
7.11.2 Equimedical Introduction and Business Overview
7.11.3 Equimedical Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Equimedical Emergency Hemostatic Agent Product Offerings
7.11.5 Equimedical Recent Development
7.12 Vascular Solutions
7.12.1 Vascular Solutions Company Information
7.12.2 Vascular Solutions Introduction and Business Overview
7.12.3 Vascular Solutions Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Vascular Solutions Emergency Hemostatic Agent Product Offerings
7.12.5 Vascular Solutions Recent Development
7.13 Marine Polymer Technologies
7.13.1 Marine Polymer Technologies Company Information
7.13.2 Marine Polymer Technologies Introduction and Business Overview
7.13.3 Marine Polymer Technologies Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Marine Polymer Technologies Emergency Hemostatic Agent Product Offerings
7.13.5 Marine Polymer Technologies Recent Development
7.14 Z-Medica
7.14.1 Z-Medica Company Information
7.14.2 Z-Medica Introduction and Business Overview
7.14.3 Z-Medica Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Z-Medica Emergency Hemostatic Agent Product Offerings
7.14.5 Z-Medica Recent Development
7.15 CryoLife
7.15.1 CryoLife Company Information
7.15.2 CryoLife Introduction and Business Overview
7.15.3 CryoLife Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2019-2024)
7.15.4 CryoLife Emergency Hemostatic Agent Product Offerings
7.15.5 CryoLife Recent Development
7.16 BioCer Entwicklungs
7.16.1 BioCer Entwicklungs Company Information
7.16.2 BioCer Entwicklungs Introduction and Business Overview
7.16.3 BioCer Entwicklungs Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2019-2024)
7.16.4 BioCer Entwicklungs Emergency Hemostatic Agent Product Offerings
7.16.5 BioCer Entwicklungs Recent Development
7.17 Biom鈥橴p SAS
7.17.1 Biom鈥橴p SAS Company Information
7.17.2 Biom鈥橴p SAS Introduction and Business Overview
7.17.3 Biom鈥橴p SAS Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2019-2024)
7.17.4 Biom鈥橴p SAS Emergency Hemostatic Agent Product Offerings
7.17.5 Biom鈥橴p SAS Recent Development
8 Industry Chain Analysis
8.1 Emergency Hemostatic Agent Industrial Chain
8.2 Emergency Hemostatic Agent Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Emergency Hemostatic Agent Sales Model
8.5.2 Sales Channel
8.5.3 Emergency Hemostatic Agent Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Ethicon
Pfizer
Baxter International
C. R. Bard
The Medicines Company
Anika Therapeutics
Advanced Medical Solutions
Integra LifeSciences
B Braun Melsungen
Gelita Medical
Equimedical
Vascular Solutions
Marine Polymer Technologies
Z-Medica
CryoLife
BioCer Entwicklungs
Biom鈥橴p SAS

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.